Lixte Biotechnology Holdings Inc. (LIXT)

[bigfart]

Another one hit wonder it moved on news

[Monksdream]

Early Barchart 100
https://www.barchart.com/stocks/performance/percent-change/advances?orderBy=percentChange&orderDir=desc

[Awl416]

NEW SCIENTIFIC PUBLICATION SHOWS LB-100, LIXTE’S LEAD CLINICAL COMPOUND, CAN FORCE CANCER CELLS TO GIVE UP THEIR CANCER-CAUSING PROPERTIES

[Awl416]

LIXTE Biotechnology Enters into Exclusive Immune Oncology Patent License Agreement with NINDS and NCI

[81vette]

Perfectly predictable chart,pullbacks to sma 100% so far

[81vette]

No debt,current ratio $7.49

[81vette]

Some $60k-$90k buys,institutional buys starting?12%currently,up2%

[81vette]

-.02 accumulation Friday,now +.115,loading going on!!

[81vette]

Not optionable,shares to short dropping

[81vette]

1.73M float/s.o. 2.25M,12Xs buying vol

[Monksdream]

LIXT new 52 week low

[Monksdream]

July 17, 2023
8:30 am ET
Preclinical Results of LIXTE Biotechnology's Collaboration with Netherlands Cancer Institute Reveal Novel Mechanism by which LIXTE's Lead Clinical Compound LB-100 Enhances Effectiveness of Immunotherapy and Chemotherapy
Globe Newswire

[Mr Rollup]

Amazing to watch 1.64 to flat same day. SEC sleeps again

[glenn1919]

LIXT......................................https://stockcharts.com/h-sc/ui?s=LIXT&p=W&b=5&g=0&id=p86431144783

[TheFinalCD]

LIXT NEWS 1.50'S


MAYBE OFFERING NEXT


WE KNOW THEY NEED IT= $$$$$$$$$$$$$$$$$$$$

[Invest-in-America]

LIXT: Just more "HYPER-STIMULATION" of the PRICE of their stock!! (HA-HA!!!)

[TheFinalCD]

1.01 WAS LOD SUCH A SHAME

[IVANj]

Still no offering… we bouncing here??

[TheFinalCD]

LIXT 1.34X1.36 could go again, if volume comes in and squeezes=

$LIXT here is the technical chart with the inside bar on daily..... i buy the dip never the rip +100 or 200% works better pic.twitter.com/k6IlsHMUIy

— Antonio Costa (@ACInvestorBlog) February 8, 2023

[TheFinalCD]

1.29 I think they want people to chase a pop before the company wakes up and announces an offer


thats what I think

[TheFinalCD]

LIXT trying 1.30 break after just dumped to 1.16 again


all these are PD's controlled by robots

[Invest-in-America]

LIXT: And gettin' even LOWER in the A.F. routine, Boss.

PS: But SOUN, BBAI, et al., all UP a bit behind that Bing Search Engine news & 'AI Voice' stuff.

[TheFinalCD]

yup 1.39

[Invest-in-America]

LIXT: Indeed, G-2-G!! Evidently, Peeps are getting --- as they should be --- rather JADED behind the obligatory, NEXT-GREAT-CANCER-CURE-OF-THE-DAY, routines!! And the subject one here, is nowhere near the HUMAN Phase studies level. And, their PR was FUNNY, to boot!!! E.g., stimulate, feed, promote, & otherwise AUGMENT the Cancer cells entire cellular STRUCTURES to such extreme extent, that they FORGET that they are indeed CANCER cells in the FIRST PLACE --- and then they will act NORMAL, & NOT want to metastasize anywhere!!!!! Where they KIDDING us all??????

[TheFinalCD]

LIXT 2.56 @ 3:30 NOW 1.50

PRETTY SICK...NO???

ITS NOT LIKE THERE WAS AN OFFERING FOR CHEAP SAKES

[Invest-in-America]

LIXT:
https://www.marketscreener.com/quote/stock/LIXTE-BIOTECHNOLOGY-HOLDI-302255/news/LIXTE-BIOTECHNOLOGY-HOLDINGS-INC-REPORTS-THAT-ITS-LEAD-CLINICAL-COMPOUND-LB-100-CAN-KILL-CANCER-42921763/

[europtiger]

Thx for the heads up… got me 3k just below 2$ but stop is in

[tortiello]

HUGE NEWS

[TheFinalCD]

https://finviz.com/quote.ashx?t=LIXT&ty=c&ta=1&p=d

[europtiger]

I belive this will see a nice move near therm

[Investinyoface]

Took a position $1.30

$LIXT

[europtiger]

Loaded 1,18

[trendzone]

Corrupted MM or short hedge fund criminals are engaged in all out corrupt manipulation in the after hours to steal shares, or use their tools of manipulation to cover shorts,this kind of criminal act by this trash needs to get burned.

[Pedro2004]

Good Morning.

I lost money on the last run. I got caught in a massive dump (like today).
I watched this a bit today, and it's the same trading pattern.
Looks like it's a combination of the company dumping shares, and heavy shorting.

[PStockPickz]

Yep in . Thanks!

[hedge_fun]

Being the savvy trader I am, I was waiting.......

to see if the $2.40 support level held.

I'm still waiting.......BWAHAHAHAHA

Congrats longs!

[Roadtojourney]

Now every company want to release similar news?? Imo

[TheFinalCD]

low ss https://finviz.com/quote.ashx?t=LIXT&ty=c&ta=1&p=d

[Man6677]

Thank you Buddy !

Very nice

[TheFinalCD]

https://ih.advfn.com/stock-market/NASDAQ/lixte-biotechnology-LIXT/stock-news/87813772/lixte-biotechnology-announces-preclinical-results

[Man6677]

Lixte Biotechnology Announces Filing of First Patent Application Resulting from Collaboration with the Netherlands Cancer Institute and the Oncode Institute to Identify the Most Promising Drug Combinations for Lead Clinical Compound, LB-100

Source: GlobeNewswire Inc.

Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT) reported that its the recent collaboration with the Netherlands Cancer Institute (NKI), Amsterdam, one of the world’s leading comprehensive cancer centers, and Stichting Oncode Institute (Oncode Institute), Utrecht, a major independent cancer research center, has led to an initial joint patent application covering LB-100 combination therapy with one of several other investigational compounds. Lixte, NKI and Oncode Institute believe that the combination therapy would provide unexpectedly strong synergistic anti-cancer effects in cancer patients.
Lixte previously announced its entry into a collaboration with the NKI and Oncode Institute to identify the most promising drugs to be used in combination with Lixte’s LB-100 or with one of Lixte’s LB-100 analogues to treat a range of cancers, as well as to identify the specific molecular mechanisms underlying the identified combinations.

John S. Kovach, MD, the founder and CEO of Lixte, commented "The new findings support the hypothesis advanced by Professor Bernards at the NKI (Dias and Bernards, Mol Onc, 2021) that rather than the usual therapeutic approach to cancer – inhibiting overactive pathways that drive cancer growth – further stimulation of those pathways can overwhelm the cancer cells, rendering them exceptionally vulnerable to particular stress-targeted drugs, while sparing the normal cells. This ‘paradoxical intervention’ is truly groundbreaking and may be applicable to a broad range of cancers."

About Lixte Biotechnology Holdings, Inc.

Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT) is a clinical-stage pharmaceutical company dedicated to discovering drugs for more effective treatments for many forms of cancer and other serious common diseases. Major drivers of cancer are defects in the switches that turn the biochemical pathways in cells on and off. Most cancer research over the past 30 years has focused on the “on” switches because the “off” switches, especially the master “off” switch protein phosphatase (PP2A), were believed to cause intolerable toxicity in patients. Lixte has achieved a breakthrough with its novel, first-in-class lead clinical compound and PP2A inhibitor, LB-100, by demonstrating that this compound is readily tolerated in cancer patients at doses associated with anti-cancer activity. This innovative approach encourages cancer cells damaged by chemotherapy or other cancer therapies to continue to replicate before repairing the damage, leading to more efficient killing of cancer cells. LB-100 is being tested in three clinical cancer treatment studies, with others in planning. www.lixte.com

Forward-Looking Statements

This announcement contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. For example, statements regarding the Company's financial position, business strategy and other plans and objectives for future operations, and assumptions and predictions about future product demand, supply, manufacturing, costs, marketing and pricing factors are all forward-looking statements. These statements are generally accompanied by words such as "intend," anticipate," "believe," "estimate," "potential(ly)," "continue," "forecast," "predict," "plan," "may," "will," "could," "would," "should," "expect" or the negative of such terms or other comparable terminology. The Company believes that the assumptions and expectations reflected in such forward-looking statements are reasonable, based on information available to it on the date hereof, but the Company cannot provide assurances that these assumptions and expectations will prove to have been correct or that the Company will take any action that the Company may presently be planning. However, these forward-looking statements are inherently subject to known and unknown risks and uncertainties. Actual results or experience may differ materially from those expected or anticipated in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, regulatory policies, available cash, research results, competition from other similar businesses, and market and general economic factors. This discussion should be read in conjunction with the Company's filings with the United States Securities and Exchange Commission at sec.gov/edgar.shtml.

Lixte Contact:
[e-mail]
General Phone: [phone]
Investor Phone: [phone]



LIXT $$$$

[Man6677]

Not much Shares traded until now , but it‘s going up and up

LIXT $$$$

[Man6677]

Nice job today here

LIXT $$$

[Man6677]

Good Volume is coming in here !

LIXT $$$$

[Man6677]

Lixte Biotechnology’s LB-100 Reported to Convert Immunologically Unresponsive (“Cold”) Tumors to Immunologically Responsive (“Hot”) Tumors

Source: GlobeNewswire Inc.

Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT), a clinical-stage drug discovery company developing pharmacologically active drugs for use in cancer treatment, announced today that in preclinical studies its lead clinical compound, LB-100, a protein phosphatase (PP2A) inhibitor, was found to increase the responsiveness of diverse cancers to immunotherapy. In Nature Communications (15 Dec 2021), lead author Yu-Ting Yen and colleagues at the China Medical University and Hospital, Taichung, Taiwan reported that treatment with LB-100 is associated with new antigen production, tumor infiltration of cytotoxic T cells, and enhanced responsiveness to immune checkpoint blockade in mouse models of colorectal, triple-negative breast, and pancreatic cancer. The authors state that “these data indicate that PP2A inhibition can be used to change the intrinsic and extrinsic factors of tumors to improve the success rate of anti-cancer immunotherapy.”
Lixte’s founder and CEO, John S. Kovach M.D, commented that “recent advances in therapy with immune checkpoint inhibitors have been a true breakthrough in the development of more effective and less toxic treatment for many cancers. Unfortunately, most cancer patients do not respond to immunotherapy. There are widespread efforts to find pharmacologic and/or immunologic ways to turn unresponsive (‘cold’) tumors into responsive (‘hot’) tumors. Cancers with a molecular abnormality termed microsatellite-instability (MSI) stemming from a defect in a DNA repair enzyme are generally ‘hot’ tumors, that is, tumors responsive to immunotherapy. Yen and colleagues now report that pharmacologic inhibition of PP2A by LB-100 modifies two distinct molecular pathways resulting in conversion of microsatellite stable (MSS) tumors into MSI tumors sensitive immune checkpoint blockade therapy.”

Dr. Kovach concluded: “The results of Yen et al. raise the possibility that the addition of LB-100 to immunotherapy may be a simple way to convert ‘cold’ into ‘hot’ tumors, thereby increasing the percentage of patients responsive to immunotherapy. Lixte recently initiated a clinical trial in patients with previously untreated extensive stage small cell lung cancer in which LB-100 is first added to chemotherapy and an immune checkpoint blocker and then administered with the immune blocker alone in the maintenance phase of treatment (NCT04560972). Lixte is interested in collaborative studies designed to determine whether LB-100 broadly enhances the benefit of immunotherapy. Immune checkpoint blockers are now approved for treatment of at least 20 cancer types.”

About Lixte Biotechnology Holdings, Inc.

Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT) is a clinical-stage pharmaceutical company dedicated to discovering drugs for more effective treatments for many forms of cancer and other serious common diseases. A major driver of cancer is defects in the switches that turn the biochemical pathways in cells on and off. Most cancer research over the past 30 years has focused on the “on” switches because the “off” switches, especially the master “off” switch protein phosphatase (PP2A), were believed to cause intolerable toxicity in patients. Lixte has achieved a breakthrough with its novel, first-in-class lead clinical compound and PP2A inhibitor, LB-100, by demonstrating that this compound is readily tolerated in cancer patients at doses associated with anti-cancer activity. This innovative approach encourages cancer cells damaged by chemo or other cancer therapies to continue to replicate before repairing the damage, leading to more efficient killing of those cells. LB-100 is being tested in three clinical cancer treatment studies with others in planning. www.lixte.com

Forward-Looking Statements

This announcement contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. For example, statements regarding the Company's financial position, business strategy and other plans and objectives for future operations, and assumptions and predictions about future product demand, supply, manufacturing, costs, marketing and pricing factors are all forward-looking statements. These statements are generally accompanied by words such as "intend," anticipate," "believe," "estimate," "potential(ly)," "continue," "forecast," "predict," "plan," "may," "will," "could," "would," "should," "expect" or the negative of such terms or other comparable terminology. The Company believes that the assumptions and expectations reflected in such forward-looking statements are reasonable, based on information available to it on the date hereof, but the Company cannot provide assurances that these assumptions and expectations will prove to have been correct or that the Company will take any action that the Company may presently be planning. However, these forward-looking statements are inherently subject to known and unknown risks and uncertainties. Actual results or experience may differ materially from those expected or anticipated in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, regulatory policies, available cash, research results, competition from other similar businesses, and market and general economic factors. This discussion should be read in conjunction with the Company's filings with the United States Securities and Exchange Commission at sec.gov/edgar.shtml.

Lixte Contact:
[e-mail]
General Phone: [phone]
Investor Phone: [phone]

LIXT $$$$

[Roadtojourney]

Same as today, seems like they have history of pnd imo??

[Man6677]

For a pump and dump it‘s holding well !

[Pedro2004]

Another pump-and-dump PR today.

[Pedro2004]

Wow. This company likes to rip-off shareholders.

[HoldEm777]

Looking more and more like $1.75 was bottom. $2.00 break would be big imo